^
    22d
    Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (clinicaltrials.gov)
    P1/2, N=340, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • AZD5069 • danvatirsen (AZD9150)
    24d
    Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML (clinicaltrials.gov)
    P1, N=38, Recruiting, Montefiore Medical Center | N=24 --> 38 | Trial completion date: Jul 2028 --> Mar 2030 | Trial primary completion date: Oct 2025 --> Jun 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • danvatirsen (AZD9150)
    7ms
    NCI-2018-01296: Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2025 --> Aug 2025 | Trial primary completion date: Apr 2025 --> Aug 2025
    Trial completion date • Trial primary completion date • Mismatch repair • IO biomarker • dMMR
    |
    Imfinzi (durvalumab) • danvatirsen (AZD9150)
    7ms
    Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (clinicaltrials.gov)
    P1/2, N=340, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2025 --> Aug 2025
    Trial completion date • IO biomarker
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • AZD5069 • danvatirsen (AZD9150)
    7ms
    HUDSON: Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (clinicaltrials.gov)
    P2, N=527, Active, not recruiting, AstraZeneca | Trial primary completion date: Sep 2026 --> Sep 2024
    Trial primary completion date • IO biomarker
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738) • Recentin (cediranib) • oleclumab (MEDI9447) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    8ms
    BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2025 --> Jan 2026
    Trial completion date
    |
    HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
    |
    FGFR3 mutation • CDKN2A deletion • FGFR fusion
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    8ms
    STAT3 Signaling Pathway in Health and Disease. (PubMed, MedComm (2020))
    We systematically discuss therapeutic strategies, including JAK inhibitors (tofacitinib, ruxolitinib), Src Homology 2 domain inhibitors (S3I-201, STATTIC), antisense oligonucleotides (AZD9150), and nanomedicine-based drug delivery systems, which enhance specificity and bioavailability while reducing toxicity. By integrating molecular mechanisms, disease pathology, and emerging therapeutic interventions, this review fills a critical knowledge gap in STAT3-targeted therapy. Our insights into STAT3 signaling crosstalk, epigenetic regulation, and resistance mechanisms offer a foundation for developing next-generation STAT3 inhibitors with greater clinical efficacy and translational potential.
    Review • Journal
    |
    IL6 (Interleukin 6)
    |
    Jakafi (ruxolitinib) • tofacitinib • GLG-302 • danvatirsen (AZD9150)
    10ms
    Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer. (PubMed, BMJ Oncol)
    In vitro experiments evaluated STAT3 inhibition in pancreatic stellate cells (PSCs) and myeloid-derived suppressor cells (MDSCs).A phase II trial employing a Simon II stage design tested the clinical efficacy of danvatirsen and durvalumab in non-small cell lung cancer (NSCLC), PDAC and mismatch repair-deficient colorectal cancer (MRD CRC). A rationale for the lack of objective responses is danvatirsen-induced myeloid immune suppression. NCT02983578.
    P2 data • Preclinical • Journal • Checkpoint inhibition • Mismatch repair
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD4 (CD4 Molecule)
    |
    MSI-H/dMMR
    |
    Imfinzi (durvalumab) • danvatirsen (AZD9150)
    11ms
    Antisense oligonucleotides-based approaches for the treatment of multiple myeloma. (PubMed, Int J Biol Macromol)
    So far, pre-clinical and clinical studies showed promising results when Bcl-2 (Genasense), Mcl-1 (ISIS2048), STAT3 (ISIS345794) and IRF4 (ION251) were targeted using ASOs-based formulations. The relevant genetic targets in ASOs-based MM therapies were described, and the research results obtained in the studies conducted so far were analyzed, with a focus on the ASOs formulations that were already included in clinical trials. In the end, current challenges, and future perspectives of antisense therapy for MM were also discussed.
    Review • Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IRF4 (Interferon regulatory factor 4)
    |
    Genasense (oblimersen) • danvatirsen (AZD9150) • frenlosirsen (ION251)
    11ms
    HUDSON: Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (clinicaltrials.gov)
    P2, N=531, Active, not recruiting, AstraZeneca | Trial completion date: Sep 2024 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738) • Recentin (cediranib) • oleclumab (MEDI9447) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    12ms
    BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2024 --> Mar 2025
    Trial completion date
    |
    HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • CD8 (cluster of differentiation 8) • CCNE1 (Cyclin E1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
    |
    PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)
    over1year
    AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer (clinicaltrials.gov)
    P1, N=76, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • danvatirsen (AZD9150)